Company Filing History:
Years Active: 2020
Title: Fleur Stevenhagen: Innovator in Cardiotoxicity Measurement
Introduction
Fleur Stevenhagen is a notable inventor based in Leiden, Netherlands. She has made significant contributions to the field of cardiotoxicity measurement through her innovative research and development.
Latest Patents
Fleur holds a patent for "Assays for measuring cardiotoxicity." This patent relates to technology designed to predict the cardiotoxicity of various compounds. The disclosure includes in vitro methods utilizing human stem-cell derived cardiomyocytes cultured in specific media. Additionally, it outlines kits that can be used in the method. In this innovative approach, the cells are treated with a test compound alongside a mitochondrial toxicant.
Career Highlights
Fleur is currently associated with Ncardia B.V., a company that focuses on cardiac safety and drug development. Her work at Ncardia has been instrumental in advancing the understanding of cardiotoxicity and improving drug safety assessments.
Collaborations
Fleur collaborates with Stefan Robbert Braam, contributing to the advancement of research in cardiotoxicity and related fields.
Conclusion
Fleur Stevenhagen's work in developing assays for measuring cardiotoxicity represents a significant advancement in the field of drug safety. Her contributions are vital for predicting the cardiotoxic effects of compounds, ultimately enhancing patient safety in drug development.